Capricor療法 CAPR 深 滬
等待開盤 05-23 09:30:00 美东时间
29.075
-0.505
-1.71%
華盛通- 最 高29.93
- 今 開29.58
- 成交量 33.15万股
- 最 低 28.89
- 昨 收 29.58
- 總市值 16.84亿
- 52周最高 40.37
- 市盈率 靜 --
- 換手率 0.57%
- 52周最低 4.30
- 委 比 94.20%
- 總股本 5791.19万
- 歷史最高 171.50
- 量 比 0.40
- 振 幅 3.52%
- 歷史最低 0.88
- 每 手 1
- 風險率 10.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
财报速睇 | Capricor疗法 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损0.34亿美元，同比亏损扩大39.2%
华盛资讯5月14日讯，Capricor疗法公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损0.34亿美元，同比亏损扩大39.2%。
05-14 07:47
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $60 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $60 price target.
05-13 19:08
Capricor Therapeutics Q1 2026 Earnings Call Transcript
Capricor Therapeutics (NASDAQ:CAPR) released first-quarter financial results an...
05-13 05:27
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
Capricor drops following filing of lawsuit against Nippon Shinyaku
Capricor Therapeutics (CAPR) is down ~11% in Friday trading after announcing following Thursday's market close it is suing Nippon Shinyaku due to a "fundamental pricing flaw" in an agreement the two c...
05-09 03:02
Capricor sues Nippon Shinyaku over US distribution rights for CAP-1002
Capricor sues Nippon Shinyaku over US distribution rights for CAP-1002 Nippon Shinyaku faces lawsuit filed May 7, 2026 in New Jersey Superior Court, Chancery Division, Bergen County by Capricor Therapeutics seeking injunction tied to commercialization and distribution agreement for CAP-1002 (deramio
05-08 16:33
Capricor Sues NS Pharma Over Deramiocel U.S. Rights
The latest update is out from Capricor Therapeutics ( ($CAPR) ). On May 7, 2026...
05-08 07:15
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
Capricor Therapeutics will release its Q1 2026 financial results on May 12, 2026, after market close. Management will host a conference call and webcast at 4:30 p.m. ET that day. Participants can join via phone or webcast using the provided details. The company, focused on developing cell and exosome-based therapies for rare diseases, recently advanced its lead candidate, Deramiocel, for Duchenne muscular dystrophy. A replay of the call will be a...
05-04 20:05
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting
Capricor Therapeutics announced the presentation of Phase 3 HOPE-3 trial data for Deramiocel in Duchenne muscular dystrophy (DMD) at the 2026 AAN Annual Meeting. The data showed statistically and clinically meaningful improvements in upper limb function and slowing of disease progression, highlighting Deramiocel's potential as a transformative therapy. The company emphasized its commitment to the DMD community and noted that the BLA for Deramioce...
04-22 13:00
